BJDX Bluejay Diagnostics, Inc.: שווי פעילות לרווח לפני ריבית, מסים ופחת

The market valuation of Bluejay Diagnostics (BJDX) on the GURU.Markets platform is visually presented as 0.00. The business is resilient to economic downturns, as urgent diagnostics remain in constant demand. Bluejay Diagnostics (BJDX) develops compact devices for instantaneous patient blood analysis, reducing diagnosis time. Growth prospects rely on the implementation of sepsis detection tests in intensive care units, regardless of market conditions.

Conservative capital demands full transparency regarding business value, including debt and tax liabilities. The EV/EBITDA ratio measures the actual enterprise value relative to its operating profit, making it possible to identify asset overvaluation or attractive entry points. The high costs and liquidity risks of Bluejay Diagnostics (BJDX) are already priced in, which confirms the shift in the company's EV/EBITDA level.